BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• 

  IN PARTNERSHIP WITH INTELLIA THERAPEUTICS

  The commercial launch playbook: Team structure, readiness and execution

  Intellia Therapeutics’s Senior Vice President Maria Natale discusses why the most successful launches are shaped long before approval, with strategy, structure and patient insight at the core.

  June 15, 2026

   · 

  6 min read

   · 

  Jennifer C. Smith-Parker
• 

  Rare diseases

  Consummate chameleon Amylyx nears regulatory run in obesity surgery complication

  After suffering the market withdrawal of its only product, Amylyx is gearing up for a pivotal Phase 3 readout in post-bariatric hypoglycemia. But the company’s driving ethos is still to treat “debilitating, devastating” neurodegenerative diseases, co-CEO Justin Klee told BioSpace.

  June 15, 2026

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Psychedelics

  Despite FDA trial clearance, ibogaine metabolite won’t receive red carpet treatment

  DemeRx is launching the first U.S. clinical trial of an ibogaine-derived drug candidate, marking a pivotal moment for a controversial psychedelic long sidelined by safety concerns.

  June 15, 2026

   · 

  10 min read

   · 

  Gabrielle Masson
• 

  Psychedelics

  How does ibogaine work? Understanding matrix logic to make a safer drug

  Ibogaine’s unconventional “matrix pharmacology” may underlie both its therapeutic promise and unpredictable cardiac risks. Unraveling this mechanism could help drug developers hoping to bring ibogaine analogs to market.

  June 15, 2026

   · 

  3 min read

   · 

  Gabrielle Masson
• Press Releases

  L7 Informatics Makes the Case for an Agentic Operating System as the Strategic Foundation for Regulated Process Industries

  L7 CEO Vasu Rangadass, Ph.D., argues that regulated process industries have reached the limits of point-solution modernization and must pivot to unified orchestration to unlock the promise of agentic AI.

  June 15, 2026

   · 

  1 min read
• Press Releases

  Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

  June 15, 2026

   · 

  12 min read
• Press Releases

  Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

  June 15, 2026

   · 

  4 min read
• Press Releases

  Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

  June 15, 2026

   · 

  8 min read
• Press Releases

  Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

  June 15, 2026

   · 

  12 min read
• Press Releases

  Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

  June 15, 2026

   · 

  14 min read